Premium
Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient
Author(s) -
Alsunaid Sammar R.,
Ashraf Humayun,
Soubani Ayman O.
Publication year - 2018
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12960
Subject(s) - medicine , lactic acidosis , tenofovir alafenamide , complication , hematopoietic stem cell transplantation , surgery , gastroenterology , transplantation , immunology , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy
Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues ( NA ) for the treatment of hepatitis B, C and HIV . No cases of such a complication have been reported in hematopoietic stem cell transplant ( HSCT ) recipients. We present a 65‐year male who underwent autologous HSCT for the treatment of multiple myeloma. Prior to transplant he was started on single agent tenofovir alafenamide ( TAF ) for treatment of resolved hepatitis B infection. He presented few weeks later with severe lactic acidosis. Other causes of lactic acidosis were excluded. The patient died of multi‐organ failure despite stopping TAF and aggressive supportive care. The case demonstrates the need for increased awareness of this potential complication of NA treatment in the course of transplantation.